Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has at least 1 year history of migraine (with or without aura)~* Females of childbearing years must use acceptable contraception throughout trial~* Patient is in general good health based on screening assessment~Exclusion Criteria:~* Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)~* Patient has heart disease, uncontrolled hypertension (high blood pressure), uncontrolled diabetes or other significant disease~* Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other then migraine)~* Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption~* Patient has a history of cancer within the last 5 years

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match assigned treatment arm; one orally-administered dose, plus an optional second dose of active drug, per assigned treatment arm, to treat a single moderate-to-severe migraine headache.
- MK0974 25 mg (Type: EXPERIMENTAL): MK0974 25 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- MK0974 50 mg (Type: EXPERIMENTAL): MK0974 50 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- MK0974 100 mg (Type: EXPERIMENTAL): MK0974 100 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- MK0974 200 mg (Type: EXPERIMENTAL): MK0974 200 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- MK0974 300 mg (Type: EXPERIMENTAL): MK0974 300 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- MK0974 400 mg (Type: EXPERIMENTAL): MK0974 400 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- MK0974 600 mg (Type: EXPERIMENTAL): MK0974 600 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- Rizatriptan 10 mg (Type: ACTIVE_COMPARATOR): Rizatriptan 10 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.

Based on this trial design, predict the completion outcome and termination type (if applicable).